MX2018011625A - Metodos para detectar bordetella. - Google Patents

Metodos para detectar bordetella.

Info

Publication number
MX2018011625A
MX2018011625A MX2018011625A MX2018011625A MX2018011625A MX 2018011625 A MX2018011625 A MX 2018011625A MX 2018011625 A MX2018011625 A MX 2018011625A MX 2018011625 A MX2018011625 A MX 2018011625A MX 2018011625 A MX2018011625 A MX 2018011625A
Authority
MX
Mexico
Prior art keywords
methods
bordetella
pertussis
detecting
holmesii
Prior art date
Application number
MX2018011625A
Other languages
English (en)
Inventor
Tabb Michelle
Chen Jules
Original Assignee
Quest Diagnostics Invest Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Diagnostics Invest Llc filed Critical Quest Diagnostics Invest Llc
Publication of MX2018011625A publication Critical patent/MX2018011625A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente descripción proporciona métodos para determinar si un paciente que exhibe síntomas similares a la tos ferina se beneficiará a partir del tratamiento con agentes terapéuticos que inhiban Bordetella holmesii. Estos métodos se basan en la detección de Bordetella pertussis, Bordetella parapertussis y Bordetella holmesii en una muestra biológica por medio del ensayo para determinar la presencia de los elementos de repetición objetivo de lS481, IS1001 y hIS1001, respectivamente. También se proporcionan los kits para utilizarse en la práctica de los métodos.
MX2018011625A 2016-03-24 2017-03-23 Metodos para detectar bordetella. MX2018011625A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662312883P 2016-03-24 2016-03-24
PCT/US2017/023735 WO2017165599A1 (en) 2016-03-24 2017-03-23 Methods for detecting bordetella

Publications (1)

Publication Number Publication Date
MX2018011625A true MX2018011625A (es) 2019-01-10

Family

ID=59899804

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018011625A MX2018011625A (es) 2016-03-24 2017-03-23 Metodos para detectar bordetella.
MX2022014741A MX2022014741A (es) 2016-03-24 2018-09-24 Metodos para detectar bordetella.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022014741A MX2022014741A (es) 2016-03-24 2018-09-24 Metodos para detectar bordetella.

Country Status (7)

Country Link
US (1) US20190382826A1 (es)
EP (2) EP4144867A1 (es)
CN (1) CN109153699A (es)
BR (1) BR112018069316A2 (es)
CA (1) CA3018843A1 (es)
MX (2) MX2018011625A (es)
WO (1) WO2017165599A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11215573B2 (en) * 2016-01-14 2022-01-04 Jamlet MONASELIDZE Differential scanning microcalorimeter device for detecting disease and monitoring therapeutic efficacy
CA3112651A1 (en) * 2018-09-27 2020-04-02 Gen-Probe Incorporated Compositions and methods for detecting bordetella pertussis and bordetella parapertussis nucleic acid
MX2021008937A (es) * 2019-01-23 2021-11-12 Glycolysis Biomed Co Ltd Compuestos de beta-lactama o sales de los mismos para su uso en la prevencion o tratamiento de accion prolongada del trastorno del metabolismo de la glucosa.
CN110468223B (zh) * 2019-09-26 2020-07-31 北京卓诚惠生生物科技股份有限公司 基于dUTP/UNG法的肺炎支原体和鲍特菌属核酸检测的引物、探针、试剂盒及方法
CN113373143A (zh) * 2021-07-13 2021-09-10 国药(武汉)医学实验室有限公司 一种用于副百日咳鲍特菌检测探针、试剂盒及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008118592A2 (en) * 2007-02-23 2008-10-02 The Penn State Research Foundation Use of an avirulent bordetella mutant as a live vaccine vector
US10465252B2 (en) * 2007-10-26 2019-11-05 Quest Diagnostics Investments Incorporated Bordetella detection assay
WO2010124281A2 (en) * 2009-04-24 2010-10-28 The Goverment Of The Usa, As Represented By The Secretary, Department Of Health And Human Services,Centres For Disease Control And Prevention Selective detection of bordetella species
BR112014000138B1 (pt) * 2011-07-06 2021-11-16 Quest Diagnostics Investments Incorporation Método para identificar a presença ou ausência de um ácido nucleico alvo
ES2662386T3 (es) * 2011-10-04 2018-04-06 Genera Biosystems Limited Composiciones y métodos para la detección patógenos respiratorios usando sondas de ácido nucleico y subconjuntos de gránulos
US20160326571A1 (en) * 2013-10-31 2016-11-10 Atherotech, Inc. Methods for nucleic acid amplification
AU2015353685B2 (en) * 2014-11-25 2021-12-23 Quest Diagnostics Investments Llc Amplification and detection of nucleic acids in a biological sample

Also Published As

Publication number Publication date
CN109153699A (zh) 2019-01-04
CA3018843A1 (en) 2017-09-28
EP3442984A4 (en) 2019-11-06
EP3442984B1 (en) 2022-08-10
MX2022014741A (es) 2023-01-11
EP4144867A1 (en) 2023-03-08
EP3442984A1 (en) 2019-02-20
BR112018069316A2 (pt) 2019-01-22
WO2017165599A1 (en) 2017-09-28
US20190382826A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
MX2022014741A (es) Metodos para detectar bordetella.
EA201790716A1 (ru) Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr
PH12017502200A1 (en) Methods of diagnosing and treating cancer
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
MX2018014922A (es) Metodos para detectar norovirus.
MX2020001193A (es) Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos.
PH12020551683A1 (en) Biomarkers for graft-versus-host disease
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
MX2023001945A (es) Composiciones y metodos para el cribado de tumores solidos.
EA202092319A1 (ru) Способы получения опухоль-инфильтрирующих лимфоцитов и применения их в иммунотерапии
BR112016020053A2 (pt) métodos de previsão da reação de pacientes que sofrem de distúrbio inflamatório, de previsão da capacidade de reação de pacientes, de identificação de pacientes que sofrem de distúrbio inflamatório e de seu tratamento, usos de kit e kits
MX2017013390A (es) Método para el tratamiento de cáncer pulmonar.
MX2019003569A (es) Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos.
WO2018183817A3 (en) Tumor burden as measured by cell free dna
MX2021012347A (es) Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
MX2019007894A (es) Composiciones y metodos para detectar el adn tumoral circulante.
NZ729773A (en) Biomarkers for disease progression in melanoma
MX2019005684A (es) Métodos para detectar mutaciones de fibrosis quística mediante el uso de extracción con puntas mitra.
MX2021007951A (es) Ensayo multiplexado y metodos de uso del mismo.
MX2021009281A (es) Metodos de deteccion de legionella.
WO2015187953A8 (en) Method for direct microbial identification
DE602008004556D1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
CL2021000251A1 (es) Métodos de identificación de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa
WO2015126922A3 (en) Rapid phenotype tests for antitubercular drug sensitivity and resistance
EA201691393A1 (ru) Методы анализа клиренса субстрата для лизосомальных ферментов